- Tumors1000+
- Pathology1000+
- Pathologic Processes1000+
- Cancer1000+
- Nervous System Diseases1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Pathology1000+
- Pathologic Processes1000+
- Cancer1000+
- Nervous System Diseases1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- PR positive
- EGFR positive
- PD-L1 negative
- EGFR negative
- ER negative
- PR negative
- ALK negative
- BRAF positive
- KRAS positive
- CD20 positive
- BRCA1 positive
- ALK positive
- p16 positive
- BRCA2 positive
- MET positive
- IDH positive
- BRAF negative
- HR positive
- HLA-A positive
- MYC positive
- ROS1 negative
- PIK3CA positive
- IDH negative
- RET positive
- ROS1 positive
- HLA positive
- TP53 positive
- p16 negative
- HPV positive
- MET negative
- dMMR positive
- BCL2 positive
- BCR-ABL1 positive
- BRCA positive
- FLT3 positive
- MSI-H positive
- BCL6 positive
- CD19 positive
- CD5 positive
- HPV negative
- NTRK positive
- L858R positive
- RAS positive
- TP53 negative
- anti-dsDNA positive
- ANA positive
- CD123 positive
- Ex19del positive
- FGFR2 positive
- HLA negative
- NF1 positive
- PALB2 positive
- RET negative
- SMN1 positive
- CCND1 positive
- CLDN18.2 positive
- HBsAg positive
- HLA-A negative
- MLH1 positive
- MSH2 positive
- MSH6 positive
- NTRK negative
- PMS2 positive
- RAS negative
- BRCA1 negative
- CD4 positive
- CFTR positive
- FGFR positive
- KRAS negative
- MSS positive
- NRAS positive
- PTEN positive
- RB1 negative
- RB1 positive
- TTR positive
- ctDNA positive
- ABCA4 positive
- BRCA2 negative
- CD20 negative
- EBV positive
- FLT3 negative
- KIT positive
- KMT2A positive
- MDM2 positive
- MGMT negative
- MMR positive
- NTRK1 positive
- PD-1 positive
- Philadelphia Chromosome positive
- RAF positive
- RF positive
- SMN2 positive
- T790M positive
- TROP2 negative
- TROP2 positive
- anti-Sm positive
- pMMR positive
- t(11;14) positive
- 1p negative
- APC positive
- APP positive
- ATM positive
- C5 positive
- CD19 negative
- CD22 negative
- CD22 positive
- CD23 positive
- CD30 positive
- CD8 positive
- COL7A1 positive
- FMR1 positive
- HBV DNA negative
- HBV DNA positive
- HEXA positive
- HEXB positive
- HPV16 positive
- HRD positive
- HbSS positive
- JAK2 positive
- Ki67 positive
- MGMT positive
- MMR negative
- MSI positive
- MSI-H negative
- NF2 positive
- PD-1 negative
- PKLR positive
- PSEN1 positive
- PSEN2 positive
- Philadelphia chromosome negative
- RHO positive
- SPINK5 positive
- TSC1 positive
- TSC2 positive
- anti-Ro autoantibodies positive
- dMMR negative
- β-thalassemia positive
- \-17/abn(17p) positive
- \-5/del(5q) positive
- \-7 positive
- 11q negative
- 11q positive
- 19q negative
- AKT negative
- ALPL positive
- Aβ1-42 positive
- BRCA negative
- CD1a positive
- CD2 positive
- CD3 positive
- CD34 positive
- CD7 positive
- CD99 positive
- CDK4 positive
- COL1A1 positive
- COL1A2 positive
- Complex karyotype positive
- DLL3 positive
- DMD positive
- DMPK positive
- EPCAM positive
- ER or PR positive
- ER/PR positive
- EZH2 positive
- FAP positive
- FGFR1 positive
- FGFR3 positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- GATA2 positive
- GBA positive
- GLA positive
- GPC3 positive
- GRN positive
- H3K27M positive
- HBB positive
- HBcAb negative
- HBcAb positive
- HBsAg negative
- HR negative
- HRAS positive
- HbE positive
- IDS positive
- IGHV negative
- IGHV positive
- KMT2A-r positive
- L861Q positive
- LKB1 positive
- MECOM positive
- MECP2 positive
- MSI negative
- MSS negative
- MYC negative
- NPM1 positive
- NRAS negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- 30-day washout period after Erythropoietin-Stimulating Agent or IV Iron
- ALK TKI Therapy
- Abrocitinib
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Active Treatment for Cutaneous Squamous Cell Carcinoma
- Active Treatment for Non-Invasive Basal Cell Carcinoma
- Adjuvant Radiation Therapy
- Adjuvant Radiation for 4-6 weeks
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
7283 trials
Trials Without a Placebo
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing an injectable medication called efgartigimod PH20 SC in people with certain muscle inflammation diseases. The goal is to see if it helps improve their condition by lowering harmful proteins in their blood. The study focuses on patients with specific subtypes of these diseases who often don't respond well to usual treatments. Efgartigimod was developed for autoimmune diseases and has been approved for treating a specific muscle condition in adults.
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests if adding a radioactive drug to standard hormone treatments can better treat men with advanced prostate cancer. The drug targets and kills cancer cells with radiation, while standard treatments block hormones that help cancer grow.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing two different treatments for men with metastatic castration resistant prostate cancer who have previously been treated with an alternate androgen receptor downregulation therapy. The study will compare how well each treatment improves the participant's rPFS (progression free survival) or death.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests an inhaler with three medications to help people with severe asthma who don't respond well to usual treatments. The inhaler reduces inflammation, relaxes muscles around the airways, and keeps them open longer. The study aims to see if this combination is more effective and safe compared to other treatments.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests if injecting special cells from a patient's own fat can reduce pain and improve function in people with knee osteoarthritis. These cells have been investigated in various studies for their potential to treat knee osteoarthritis by reducing pain and improving function.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a combination of drugs to see if they are effective in reducing the chance of cancer recurrence or developing new cancers.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares a new treatment, frexalimab, with an existing pill, teriflunomide, in adults aged 18-55 who have relapsing multiple sclerosis. The study aims to see if frexalimab can reduce the frequency of symptom relapses better than teriflunomide. Participants will be monitored over several years.
Efficacy & Safety Awards
Pivotal Trial
Get notified when new Vitiligo trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will evaluate if the drug upadacitinib is safe and effective in treating vitiligo, a chronic autoimmune skin disease. 540 participants will be enrolled worldwide to receive either upadacitinib or a placebo in Period A, followed by upadacitinib in Period B.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called TAK-279 to see if it can help people with moderate to severe plaque psoriasis. The study will compare TAK-279 to an existing treatment called apremilast, which is approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. The goal is to find out if TAK-279 can better reduce the skin problems associated with this condition.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called NMRA-335140 to see if it helps people with major depressive disorder. It includes participants who have no safety concerns. The medication aims to improve mood by affecting brain chemicals.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called NMRA 335140 to see if it can help people with Major Depressive Disorder feel less depressed. The study involves an initial evaluation and a treatment phase where participants will receive either the medication or an inactive substance. The medication likely works by changing brain chemicals that affect mood.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called Pegozafermin to see if it can lower high levels of fats in the blood in people with severe hypertriglyceridemia. These patients have very high triglyceride levels, which can lead to serious health issues. The medication aims to reduce these fat levels to improve their health.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studied if digital therapies plus standard care can reduce symptoms of schizophrenia in teens & adults.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing gotistobart, a new drug that helps the immune system fight advanced lung cancer in patients who haven't responded to other treatments. It works by blocking a protein that allows cancer cells to hide from the immune system.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Erosive Esophagitis trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests BLI5100, an oral medication, in patients with Erosive Esophagitis (EE). It aims to see if BLI5100 can heal the esophagus and maintain its healing.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called ritlecitinib, which is taken as oral capsules. It aims to help adults and adolescents who have non-segmental vitiligo, a condition that causes skin to lose its color. The medication works by managing the immune system to stop the skin from losing its color.
Efficacy & Safety Awards
Pivotal Trial
1
2
3
…50